AbbVie Inc. $ABBV Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D increased its stake in AbbVie Inc. (NYSE:ABBV) by 3.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 617,051 shares of the company’s stock after acquiring an additional 21,810 shares during the period. AbbVie makes up approximately 0.5% of State of New Jersey Common Pension Fund D’s investment portfolio, making the stock its 26th biggest position. State of New Jersey Common Pension Fund D’s holdings in AbbVie were worth $142,872,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $39,000. Finally, Access Investment Management LLC acquired a new stake in AbbVie during the second quarter valued at approximately $44,000. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

NYSE ABBV opened at $231.57 on Friday. The company has a 50 day simple moving average of $223.56 and a 200-day simple moving average of $220.85. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market capitalization of $409.28 billion, a price-to-earnings ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the business posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ABBV. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Guggenheim boosted their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Citigroup decreased their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Finally, BMO Capital Markets restated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $251.00.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.